CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion
Authors:
- 1 September 2018
- journal article
- review article
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 93, 15-25
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay ParadigmSLAS Discovery, 2016
- Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytesJournal of Pharmacological and Toxicological Methods, 2015
- Results From the IQ‐CSRC Prospective Study Support Replacement of the Thorough QT Study by QT Assessment in the Early Clinical PhaseClinical Pharmacology & Therapeutics, 2014
- Differentiating Drug-Induced Multichannel Block on the Electrocardiogram: Randomized Study of Dofetilide, Quinidine, Ranolazine, and VerapamilClinical Pharmacology & Therapeutics, 2014
- Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research ConsortiumAmerican Heart Journal, 2014
- The impact of drug-related QT prolongation on FDA regulatory decisionsInternational Journal of Cardiology, 2013
- Integrated risk assessment and predictive value to humans of non‐clinical repolarization assaysBritish Journal of Pharmacology, 2010
- The effect of changes in core body temperature on the QT interval in beagle dogs: a previously ignored phenomenon, with a method for correctionBritish Journal of Pharmacology, 2008
- Dolasetron-induced torsades de pointesJournal of Clinical Anesthesia, 2007
- Investigation of the effects of physiological and vasodilation-induced autonomic activation on the QTc Interval in healthy male subjectsBritish Journal of Clinical Pharmacology, 2005